Brian HicksPosted March 5, 2010
Wealth Daily Editor Greg McCoach comments on investment guru George Soros' recent move to double down on gold, and why his hedge fund is doing the same...
Brian HicksPosted March 5, 2010
To say that "only" 36,000 people lost their jobs is a good thing is pathetic. Take a look at Harry Reid on the Hill floor.
Brian HicksPosted March 4, 2010
According to the Mortgage Banker's Association, U.S. residential mortgage originations will plunge 40 percent this year to the lowest level in a decade, and the reasons for this are simple.
Brian HicksPosted March 4, 2010
Wealth Daily Editor Steve Christ takes a look at Warren Buffett's Annual Letter to Shareholders and points out the highlights.
Luke BurgessPosted March 4, 2010
Mid-Tier gold producer Lihir Gold reported production targets for the company's mines for the next decade, highlighting plans for significant increases in gold output.
Brian HicksPosted March 3, 2010
Wealth Daily Publisher Brian Hicks shares his thoughts on what he believes to be government plans to reform individual retirement plans, and why you should make as much money as you can now.
Brian HicksPosted March 3, 2010
Enormous amount of hidden borrowing may translate to incredible debt for China.
Brian HicksPosted March 2, 2010
The rumor mill is spinning and a buyout may be on the horizon for Dendreon. FDA approvals could mean potential profits for a buyer.
Nick HodgePosted March 2, 2010
Wealth Daily Editor Nick Hodge discusses new perspectives on stock market strategy after a recent fishing trip to the Gulf of Mexico.
Luke BurgessPosted March 1, 2010
Copper prices jumped and mining shares surged today as the market absorbed the weekend's 8.8 magnitude earthquake in Chile, the world's largest producer.
Brian HicksPosted March 1, 2010
Wealth Daily Analyst Adam Sharp tells readers why TLAB is his first pick for a stock in an age where the smart phone is pushing wireless networks to the breaking point...
Brian HicksPosted March 1, 2010
Faced with shrinking pipelines and falling revenues, the old way developing drugs through chemistry alone is giving way to modern technologies and that's where biotech dominates.